***4/7/2017 NEWS UPDATE*** Reports Success From Recent Cannabis Study On Cancer LINK: http://goo.gl/EIHBuC ***4/3/2017 NEWS UPDATE*** Cannabics Pharmaceuticals Inc. Receives the Final Report of Its
Research on Antitumor Properties of Cannabinoids Held in Israel Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine". LINK: http://goo.gl/WXOXhW
Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics SR' CAPSULES
Long acting oil capsule that provides a safe, effective and reliable administration of cannabis.
Cannabics SR' Capsules, Technology Description - Route of administration
There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy.
The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.
The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process. The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.
Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.
Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome...!
BETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intended for naïve patient who have not tried cannabis in the past.
Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."
The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.
The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :
https://clinicaltrials.gov/ct2/show/NCT02359123
"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.
http://www.cannabics.com/investors
http://www.otcmarkets.com/stock/CNBX/profile What is A Cannabinoid? You’ve heard by now that marijuana is a powerful medicinal herb. But, just how powerful is it? The list of medical benefits for these top 10 cannabinoids seems endless.
| | Market Value1 | $72,404,107 | a/o Jan 13, 2017 |
 | Authorized Shares | 900,000,000 | a/o Dec 30, 2016 |
| Outstanding Shares | 107,265,344 | a/o Dec 30, 2016 |
| -Restricted | 90,368,887 | a/o Dec 30, 2016 |
| -Unrestricted | 16,896,457 | a/o Dec 30, 2016 |
| | Held at DTC | Not Available |
| Float | 14,295,638 | a/o Jun 30, 2016 |
| | Par Value | 0.0001 |
CNBX Security Details Share Structure
| | Market Value1 | $37,994,466 | a/o Oct 28, 2016 |
| | Authorized Shares | 900,000,000 | a/o Jul 09, 2015 |
| | Outstanding Shares | 107,026,665 | a/o Jun 30, 2016 |
| | -Restricted | Not Available |
| | -Unrestricted | Not Available |
| | Held at DTC | Not Available |
| | Float | 18,737,071 | a/o Jun 30, 2016 |
| | Par Value | 0.0001 |